nmdp logo

After the Results: Functional vs. Chronological Age

The Case for HCT in the Treatment of MDS in Older Patients

July 29, 2021


The Blood and Marrow Transplant Clinical Trials Network (BMT CTN) 1102 study published in the Journal of Clinical Oncology clearly demonstrated that allogeneic hematopoietic cell transplant (HCT) outcomes among older patients with selected comorbidities and good functional status have similar outcomes to younger patients.

During the one-hour on-demand webinar, our experts discuss the results of this multi-center, biologic assignment trial in older patients with high-risk myelodysplastic syndrome (MDS), which defined the benefit of HCT over non-HCT therapy.

Access on-demand webinar

Learning Objectives

  • How age alone is not a contraindication to treatment due to advances in HCT
  • Why older patients with select comorbidities and good functional status can safely undergo HCT while preserving quality of life
  • Barriers and potential solutions to improve utilization of HCT for MDS
  • Efforts of the BMT CTN Taskforce on Evidence into Practice to disseminate the results of the study
  • How clinicians can access HCT coverage for Medicare-age patients with MDS
  • Implications for your practice


Steven Devine, MD
Chief Medical Officer, NMDP
Associate Scientific Director, CIBMTR® (Center for International Blood and Marrow Transplant Research®)

Stephen Spellman
Vice President of Research and Senior Scientific Director, CIBMTR

Corey S. Cutler, MD, MPH, FRCP(C)
Medical Director, Stem Cell Transplantation Program, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School

Nandita Khera, MD, MPH
Associate Professor of Medicine, Mayo Clinic Alix School of Medicine
Stem Cell Transplant Physician, Mayo Clinic

J. Douglas Rizzo, MD, MS
Senior Scientific Director, CIBMTR
Cancer Service Line Director, Froedtert & the Medical College of Wisconsin

Target Audience

Hematology/oncology physicians and nurses; HCT physicians, nurses and coordinators; NMDP clinical operations partners; and advanced level case managers and health professionals.


Access the full study published in the Journal of Clinical Oncology.